Not Medicare Enrolled

Dr. Marco Renazco, M.D.

Psychiatry · Katy, TX
Speaking/Promotional
707 S FRY RD, Katy, TX 77450
2815993313
In practice since 2006 (19 years)
NPI: 1518038751 verify on NPPES ↗
Moderate
DATA COVERAGE
Data in 2 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Renazco from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Renazco? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Renazco

Dr. Marco Renazco is a psychiatry in Katy, TX, with 19 years in practice.

Between the years covered by Open Payments, Dr. Renazco received a total of $36,198 from 38 pharmaceutical and/or device companies across 382 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in psychiatry. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Renazco is Moderate — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice$ $36,198 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$36,198
Total received (2018-2024)
Avg $5,171/year across 7 years
Top 4% in TX for psychiatry
38
Companies
382
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$28,065 (77.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,743 (15.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,391 (6.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,114
2023
$1,410
2022
$3,227
2021
$3,598
2020
$10,802
2019
$9,058
2018
$6,990

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Allergan Inc.
$11,934
Allergan, Inc.
$11,800
Janssen Pharmaceuticals, Inc
$2,651
ABBVIE INC.
$2,556
AbbVie Inc.
$1,406
US WorldMeds, LLC
$768
Takeda Pharmaceuticals U.S.A., Inc.
$606
Vanda Pharmaceuticals Inc.
$577
Otsuka America Pharmaceutical, Inc.
$469
Lundbeck LLC
$407
Corium, LLC
$387
Bausch Health US, LLC
$370
ITI, Inc.
$304
Supernus Pharmaceuticals, Inc.
$223
Neos Therapeutics, LP
$205
Teva Pharmaceuticals USA, Inc.
$178
Ironshore Pharmaceuticals Inc.
$127
Axsome Therapeutics, Inc.
$107
IDORSIA PHARMACEUTICALS US INC
$107
Shire North American Group Inc
$104
Noven Therapeutics, LLC
$103
Eisai Inc.
$102
Indivior Inc.
$96
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$84
Alkermes, Inc.
$76
Tempus AI, Inc
$70
JAZZ PHARMACEUTICALS INC.
$69
Almatica Pharma LLC
$48
Adlon Therapeutics L.P.
$42
Vertical Pharmaceuticals, LLC
$38
Avanir Pharmaceuticals, Inc.
$34
Neuronetics, Inc.
$27
EISAI INC.
$25
Brainsway USA INC
$25
Neurocrine Biosciences, Inc.
$19
Orexo US, Inc.
$19
Tris Pharma Inc
$17
Otsuka Pharmaceutical Development & Commercialization, Inc.
$17
Top 3 companies account for 72.9% of total payments
Associated products mentioned in payments ›
ABILIFY MAINTENA · ADHANSIA XR · APLENZIN · ARISTADA · AUSTEDO · AZSTARYS · Adzenys XR-ODT · Auvelity · Azstarys · BRINTELLIX · Brainsway Deep TMS System · CAPLYTA · Cotempla XR-ODT · Dayvigo · Dyanavel XR · FANAPT · Fanapt · HETLIOZ · INGREZZA · INVEGA SUSTENNA · INVEGA TRINZA · JORNAY PM · Jornay PM 20mg capsules (Bottle of 100) · LOREEV XR · Lucemyra/Lofexidine · METHYLPHENIDATE 72 · MYDAYIS · NEUROSTAR TMS THERAPY · NUEDEXTA · PERSERIS · QELBREE · QUVIVIQ · Qelbree · REXULTI · Relexxii · SECUADO · SPRAVATO · SUBLOCADE · SUBOXONE SUBLINGUAL FILM · SUNOSI · Secuado · TRINTELLIX · Tempus Pixel · Trintellix · VRAYLAR · VYVANSE · WELLBUTRIN · Xelstrym · Zubsolv
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (78%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in psychiatry and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for psychiatry in TX.

Looking for a psychiatry in Katy?
Compare psychiatrys in the Katy area by procedure volume, costs, and industry payment transparency.
Browse psychiatrys nearby

Geographic Context

Psychiatrys within 10 mi
716
Per 100K population
15.0
County median income
$73,104
Nearest hospital
OCEANS BEHAVIORAL HOSPITAL OF KATY
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment— Not enrolledN/A
Practice Data— No dataN/A
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 2 of 4 available federal datasets, with a Data Coverage level of Moderate. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Renazco is a psychiatry, and high industry engagement (speaking/promotional, top 4%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Renazco receive payments from pharmaceutical companies?
Yes. Dr. Renazco received a total of $36,198 from 38 companies across 382 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently Moderate for Dr. Renazco) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →